Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Coya Therapeutics, Inc.NASDAQ: COYA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $4.1M fell 21.4% year over year, behind the +26273.1% change in trailing-twelve-month research & development. Sequentially, it fell 39.0% from the prior quarter. Over 3 fiscal years it compounded at +50.2% a year.
Context
- Research & development amounted to 210.6% of revenue in FY2025, down 124.0 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -21.4% toward the trailing-twelve-month pace of +26273.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 16.73M USD
- Year-over-year change
- +40.7%
- 4-year CAGR
- +60.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.73M | +40.7% |
| FY2024 | 2024-12-31 | 11.89M | +96.7% |
| FY2023 | 2023-12-31 | 6.04M | +22.4% |
| FY2022 | 2022-12-31 | 4.94M | +94.2% |
| FY2021 | 2021-12-31 | 2.54M | — |
Research & Development vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's LTM Mar 2026 research & development of $3.68B is the highest of the 11 companies compared; the peer median is $35.85M.
- Its year-over-year change of +26273.1% is the highest of 11, against a peer median of -18.9%.
- Research & development amounts to 46313.4% of revenue for COYA, versus a peer median of 2026.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.68B | +26273.1% | +50.2% | 46313.4% | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $108.76M | -25.2% | -14.7% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $99.41M | +115.1% | +40.7% | — |
| LTM Mar 2026 | $79.04M | -54.8% | +4.0% | — | |
| LTM Mar 2026 | $36.3M | -40.4% | -24.8% | 3629.9% | |
| LTM Mar 2026 | $35.41M | +46.4% | +65.0% | — | |
| LTM Mar 2026 | $30.07M | -8.9% | +1.3% | 422.2% | |
| LTM Mar 2026 | $20.26M | +102.3% | +57.1% | — | |
| LTM Mar 2026 | $12.86M | -17.9% | -24.0% | 9596.3% | |
| LTM Mar 2026 | $5.77M | -21.5% | -38.7% | — | |
| Peer median (excluding COYA) | $35.85M | -18.9% | -5.5% | 2026.1% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6M | 3.55M | 7.95M |
| Cost of Revenue | 0 | 4.41M | 5.5M | 11.87M | 27.36K |
| Gross Profit | 0 | (4.41M) | 500.68K | (8.31M) | 7.92M |
| Gross Margin | — | — | 8.3% | -233.9% | 99.7% |
| Research & Development | 2.54M | 4.94M | 6.04M | 11.89M | 16.73M |
| Selling, General & Admin | 2.31M | 4.85M | 7.83M | 8.89M | 11.45M |
| Operating Expenses | 4.87M | 5.4M | 8.4M | 8.94M | 28.18M |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| EBITDA | (4.88M) | (9.26M) | (7.33M) | (17.2M) | (21.2M) |
| EBITDA Margin | — | — | -122.2% | -483.9% | -266.8% |
| Operating Income | (4.87M) | (9.81M) | (7.9M) | (17.25M) | (20.27M) |
| Operating Margin | — | — | -131.7% | -485.4% | -255.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (21.48K) | (2.43M) | 639.37K | 1.65M | (957.4K) |
| Income Before Tax | (4.89M) | (12.24M) | (7.26M) | (15.6M) | (21.22M) |
| Pre-Tax Margin | — | — | -121.0% | -439.0% | -267.1% |
| Income Tax Expense | 0 | 0 | 723.85K | (720.29K) | 3.09K |
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Net Margin | — | — | -133.1% | -418.7% | -267.1% |
| EPS (Basic) | (0.74) | (1.23) | (0.79) | (0.98) | (1.27) |
| EPS (Diluted) | (0.74) | (1.23) | (0.79) | (0.98) | (1.27) |
| Weighted Avg Shares | 6.6M | 9.95M | 10.16M | 15.24M | 16.73M |
| Weighted Avg Shares (Diluted) | 6.6M | 9.95M | 10.16M | 15.24M | 16.73M |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.